<DOC>
	<DOCNO>NCT00102479</DOCNO>
	<brief_summary>The purpose trial ass safety , tolerability pharmacokinetics aripiprazole tablet follow oral administration child adolescent .</brief_summary>
	<brief_title>Aripiprazole Pharmacokinetics ( PK ) Tolerability Study Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Children adolescents 1017 year , good physical health , preferentially primary schizophrenia spectrum diagnosis bipolar spectrum disorder History mental retardation Any neurological disorder exception Pervasive Developmental Disorder ( PDD ) , Attention Deficit Hyperactivity Disorder ( ADHD ) , Tourette â€™ Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Pharmacokinetics ,</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>acute mania pediatric population</keyword>
</DOC>